<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02017340</url>
  </required_header>
  <id_info>
    <org_study_id>NILVAD2012</org_study_id>
    <secondary_id>2012-002764-27</secondary_id>
    <secondary_id>279093</secondary_id>
    <nct_id>NCT02017340</nct_id>
  </id_info>
  <brief_title>A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease</brief_title>
  <acronym>NILVAD</acronym>
  <official_title>A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof Brian Lawlor</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Dublin, Trinity College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Molecular Medicine Ireland LBG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alzheimer Europe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Archer Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>E-Search Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College Dublin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Di Ricerche Farmacologiche Mario Negri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Szeged University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Goeteborgs Universitet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College Cork</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stichting Katholieke Universiteit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. James's Hospital, Ireland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alzheimer's disease (AD) is an ever-increasing public health concern among the aging
      population and is the most common form of dementia affecting more than 15 million individuals
      worldwide and around 5 million Europeans. The direct and indirect costs of AD and other
      dementias amount to more than €440,000 million each year (www.alz.org, 2010).

      Even modest therapeutic advances that delay disease onset and progression could significantly
      reduce the global burden of the disease and the level of care required by patients. While
      there are symptomatic-based drug therapies available for AD, these medications do not prevent
      the disease process itself. There is therefore an imperative to develop new treatments for AD
      that have disease modifying effects. This double-blind placebo controlled study will test the
      efficacy and safety of nilvadipine in 500 subjects with mild to moderate AD over a treatment
      period of 18 months. There is a strong scientific rationale for this study: Nilvadipine, a
      licensed calcium channel enhances Aß clearance from brain and restores cortical perfusion in
      mouse models of AD. Nilvadipine is safe and well tolerated in AD patients and clinical
      studies with this medication have shown stabilization of cognitive decline and reduced
      incidence of AD, pointing to both symptomatic and disease modifying benefits. Male and female
      patients with mild to moderate AD aged between 50 and 90 with a range of medical morbidities
      and frailty will be included in the study. If this trial is successful, nilvadipine would
      represent an advance in the treatment of AD patients and would have a major impact on the
      health and social care costs incurred in Europe by this neurodegenerative disorder.
      Furthermore, the creation of the NILVAD network will support future clinical trials and
      research innovation in AD across Europe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Please see 'Brief Summary', above
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2013</start_date>
  <completion_date type="Actual">December 16, 2016</completion_date>
  <primary_completion_date type="Actual">December 16, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale (ADAS) Cog</measure>
    <time_frame>18 months</time_frame>
    <description>The Alzheimer's Disease Assessment Scale (Cognitive) (Mohs et al. 1983) ADAS-cog 12 is a primary efficacy outcome measure, and includes 12 items of cognitive evaluation, namely immediate word recall, naming objects and fingers, commands, constructional praxis, ideational praxis, orientation, word recognition, remembering test instructions, spoken language ability, word-finding difficulty in spontaneous speech, comprehension &amp; delayed recall. A higher ADAS-cog score indicates a poorer cognitive function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Dementia Rating Scale Sum of Boxes (CDR-sb)</measure>
    <time_frame>18 months</time_frame>
    <description>Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) (Morris et al 1993) is the secondary efficacy outcome measure. This is a semi-structured interview with the caregiver and the patient. The patient's performance in the domains of memory, orientation, judgment, problem solving, community affairs, home and hobbies and personal care are assessed. The CDR-sb is scored from 0-18, with the higher score indicated greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability Assessment for Dementia (DAD)</measure>
    <time_frame>18 months</time_frame>
    <description>Disability Assessment for Dementia (DAD) (Gelinas et al. 1999) is a key secondary efficacy outcome measure and evaluates the basic and instrumental activities in daily activities of elderly people with dementia. This 40-item scale addresses a range of functional domains: eating, meal preparation, telephoning, hygienic, dressing, medication, corresponding, finance, leisure, and housework.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">511</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>250 patients will receive the placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nilvadipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>250 patient will receive the active drug Nilvadipine 8mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilvadipine</intervention_name>
    <description>8mg of Nilvadipine taken once a day at lunch time for 78 weeks</description>
    <arm_group_label>Nilvadipine</arm_group_label>
    <other_name>Also known as Nilvadil (Brand Name)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>8mg Placebo tablet taken once a day at lunch time for 78 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age range: Adult subjects, males and females over age 50 years.

          2. Prior diagnosis of mild to moderate probable AD based on NINCDS-ADRDA criteria (see
             Appendix B) and

          3. Standardised Mini-Mental State Examination (SMMSE) score &gt; 12 on stable dose (&gt;3
             months of cholinesterase inhibitor and or memantine). Subjects who are not on
             cholinesterase inhibitors or memantine due to poor tolerability and/or who will not
             require treatment with these medications during the course of the study can be
             included.

          4. Collateral informants such as a spouse, family member, close friend. The informant
             must have close contact with the subject and agree to monitor/manage study drug
             adherence, observe for possible adverse events, assist with psychometric measures
             requiring informant information, and accompany the subject to all evaluation visits.

          5. Fluency in relevant language sufficient to reliably complete all study assessments.

          6. Systolic BP &gt; 100 mmHg but ≤ 159 mmHg, and diastolic BP &gt; 65 mmHg but ≤ 99 mmHg on
             resting office based BP measurements, or a Systolic BP &gt; 105 mmHg but ≤ 140 mmHg, and
             diastolic BP &gt; 70 mmHg but ≤ 90 mmHg on ABPM measurement

        Exclusion Criteria:

          1. Subjects with co-morbid dementia due to other neurological disorders such as
             Parkinson's disease, vascular dementia, Huntington's disease, Pick's disease,
             Creutzfeldt-Jakob disease, normal pressure hydrocephalus, brain tumor, progressive
             supranuclear palsy, seizure disorder, subdural hematoma, or multiple sclerosis, as
             well as subjects with HIV disease, neurosyphilis, history of significant head trauma
             with loss of consciousness followed by persistent neurological deficits, known
             structural brain abnormalities, or any other condition known to interfere with
             cognitive function.

          2. Subjects currently taking any calcium channel blocker or Beta-blocker

          3. Subjects who in the opinion of the investigator, have a medical condition that would
             preclude them from participating in the study (e.g.hemodynamically significant
             coronary artery disease., chronic heart failure, syncope within the past year,
             significant valvular heart disease i.e. severe aortic and mitral stenosis..
             symptomatic orthostatic hypotension within the last year, subjects requiring more than
             one agent to control BP.), or subjects who in the opinion of the investigator are
             unlikely to complete per protocol due to care issues etc:

          4. Current Axis I diagnosis of schizophrenia, bipolar disorder, major depression.
             Subjects who are currently or who have within the past year met criteria for drug or
             alcohol abuse or dependence.

          5. Pregnant women or women who may possibly become pregnant.

          6. Subjects with a history of hypersensitivity to nilvadipine (Nivadil).

          7. Subjects who have taken an investigational or other unapproved drug during the 30 days
             or five half-lives, whichever is longer, prior to baseline.

          8. Subjects who are participating in other research studies.

          9. Patients with a SBP of ≤ 100 mmHg and/or a DBP of ≤ 65 mmHg on office based BP
             measurements, or a SBP ≤ 105 mmHg and/or a DBP of ≤ 70 mmHg on ABPM will not be
             included in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Lawlor, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Trinity College Dublin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire d'Amiens (CHU Amiens)</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bethune (CH Bethune)</name>
      <address>
        <city>Bethune</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Caen (CHU Caen)</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Calais (CHU Calais)</name>
      <address>
        <city>Calais</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Lens (CHU Lens)</name>
      <address>
        <city>Lens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional et Universitaire de Lille (CHRU Lille)</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Saint Philibert (GHICL)</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;G. Papanicolaou&quot; Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;G.Papageorgiou&quot; Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AXEPA Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szeged University</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Cork</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Castellanza</name>
      <address>
        <city>Castellanza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Genoa</name>
      <address>
        <city>Genoa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Milan</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Arnhem</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gothenburg Univeristy</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.nilvad.eu/</url>
    <description>NILVAD project website</description>
  </link>
  <reference>
    <citation>Brogden RN, McTavish D. Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina. Drugs Aging. 1995 Feb;6(2):150-71. Review. Erratum in: Drugs Aging 1995 Aug;7(2):116.</citation>
    <PMID>7711361</PMID>
  </reference>
  <reference>
    <citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.</citation>
    <PMID>3558716</PMID>
  </reference>
  <reference>
    <citation>Facchinetti F, Fasolato C, Del Giudice E, Burgo A, Furegato S, Fusco M, Basso E, Seraglia R, D'Arrigo A, Leon A. Nimodipine selectively stimulates beta-amyloid 1-42 secretion by a mechanism independent of calcium influx blockage. Neurobiol Aging. 2006 Feb;27(2):218-27.</citation>
    <PMID>16399208</PMID>
  </reference>
  <reference>
    <citation>Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1977;17:149-66. Review.</citation>
    <PMID>326161</PMID>
  </reference>
  <reference>
    <citation>Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998 Oct 24;352(9137):1347-51.</citation>
    <PMID>9802273</PMID>
  </reference>
  <reference>
    <citation>Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhäger WH; Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002 Oct 14;162(18):2046-52. Erratum in: Arch Intern Med. 2003 Jan 27;163(2):241..</citation>
    <PMID>12374512</PMID>
  </reference>
  <reference>
    <citation>Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56.</citation>
    <PMID>11253156</PMID>
  </reference>
  <reference>
    <citation>Furuichi Y, Takakura S, Satoh H, Mori J, Kohsaka M. The effect of nilvadipine, a dihydropyridine type calcium channel blocker, on local cerebral blood flow in rats. Jpn J Pharmacol. 1992 Apr;58(4):457-60.</citation>
    <PMID>1405041</PMID>
  </reference>
  <reference>
    <citation>Gélinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther. 1999 Sep-Oct;53(5):471-81.</citation>
    <PMID>10500855</PMID>
  </reference>
  <reference>
    <citation>Hanyu H, Hirao K, Shimizu S, Sato T, Kiuchi A, Iwamoto T. Nilvadipine prevents cognitive decline of patients with mild cognitive impairment. Int J Geriatr Psychiatry. 2007 Dec;22(12):1264-6.</citation>
    <PMID>18033677</PMID>
  </reference>
  <reference>
    <citation>Inouye M, Mio T, Sumino K. Nilvadipine protects low-density lipoprotein cholesterol from in vivo oxidation in hypertensive patients with risk factors for atherosclerosis. Eur J Clin Pharmacol. 2000 Apr;56(1):35-41.</citation>
    <PMID>10853875</PMID>
  </reference>
  <reference>
    <citation>Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, Tschanz JT, Mayer LS, Welsh-Bohmer KA, Breitner JC. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol. 2006 May;63(5):686-92. Epub 2006 Mar 13.</citation>
    <PMID>16533956</PMID>
  </reference>
  <reference>
    <citation>Kagawa H, Nomura S, Ozaki Y, Nagahama M, Fukuhara S. Effects of nilvadipine on cytokine-levels and soluble factors in collagen disease complicated with essential hypertension. Clin Exp Hypertens. 1999 Oct;21(7):1177-88.</citation>
    <PMID>10513835</PMID>
  </reference>
  <reference>
    <citation>López-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2002;(3):CD000147. Review.</citation>
    <PMID>12137606</PMID>
  </reference>
  <reference>
    <citation>Lubben J, Blozik E, Gillmann G, Iliffe S, von Renteln Kruse W, Beck JC, Stuck AE. Performance of an abbreviated version of the Lubben Social Network Scale among three European community-dwelling older adult populations. Gerontologist. 2006 Aug;46(4):503-13.</citation>
    <PMID>16921004</PMID>
  </reference>
  <reference>
    <citation>Maxwell CJ, Hogan DB, Ebly EM. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging. CMAJ. 1999 Sep 7;161(5):501-6. Erratum in: CMAJ 1999 Nov 30;161(11):1396.</citation>
    <PMID>10497605</PMID>
  </reference>
  <reference>
    <citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939-44.</citation>
    <PMID>6610841</PMID>
  </reference>
  <reference>
    <citation>Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull. 1983;19(3):448-50.</citation>
    <PMID>6635122</PMID>
  </reference>
  <reference>
    <citation>Molloy DW, Standish TI. A guide to the standardized Mini-Mental State Examination. Int Psychogeriatr. 1997;9 Suppl 1:87-94; discussion 143-50.</citation>
    <PMID>9447431</PMID>
  </reference>
  <reference>
    <citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993 Nov;43(11):2412-4.</citation>
    <PMID>8232972</PMID>
  </reference>
  <reference>
    <citation>Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989 Sep;39(9):1159-65.</citation>
    <PMID>2771064</PMID>
  </reference>
  <reference>
    <citation>Ogasawara K, Noda A, Yasuda S, Kobayashi M, Yukawa H, Ogawa A. Effect of calcium antagonist on cerebral blood flow and oxygen metabolism in patients with hypertension and chronic major cerebral artery occlusion: a positron emission tomography study. Nucl Med Commun. 2003 Jan;24(1):71-6.</citation>
    <PMID>12501022</PMID>
  </reference>
  <reference>
    <citation>Ohtsuka M, Ono T, Hiroi J, Esumi K, Kikuchi H, Kumada S. Comparison of the cardiovascular effect of FR34235, a new dihydropyridine, with other calcium antagonists. J Cardiovasc Pharmacol. 1983 Nov-Dec;5(6):1074-82.</citation>
    <PMID>6196557</PMID>
  </reference>
  <reference>
    <citation>Parry SW, Steen N, Baptist M, Fiaschi KA, Parry O, Kenny RA. Cerebral autoregulation is impaired in cardioinhibitory carotid sinus syndrome. Heart. 2006 Jun;92(6):792-7. Epub 2006 Jan 31.</citation>
    <PMID>16449521</PMID>
  </reference>
  <reference>
    <citation>Rosenthal J. Nilvadipine: profile of a new calcium antagonist. An overview. J Cardiovasc Pharmacol. 1994;24 Suppl 2:S92-107. Review.</citation>
    <PMID>7898101</PMID>
  </reference>
  <reference>
    <citation>Shimamoto H, Shimamoto Y. Nilvadipine increases cerebral blood flow in elderly hypertensives: comparison with nifedipine. J Hum Hypertens. 1995 Apr;9(4):271-9.</citation>
    <PMID>7595910</PMID>
  </reference>
  <reference>
    <citation>Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry. 1990 May 15;27(10):1133-42.</citation>
    <PMID>2187540</PMID>
  </reference>
  <reference>
    <citation>Verghese J, Lipton RB, Katz MJ, Hall CB, Derby CA, Kuslansky G, Ambrose AF, Sliwinski M, Buschke H. Leisure activities and the risk of dementia in the elderly. N Engl J Med. 2003 Jun 19;348(25):2508-16.</citation>
    <PMID>12815136</PMID>
  </reference>
  <reference>
    <citation>Yasar S, Corrada M, Brookmeyer R, Kawas C. Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol Aging. 2005 Feb;26(2):157-63.</citation>
    <PMID>15582745</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2013</study_first_submitted>
  <study_first_submitted_qc>December 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. James's Hospital, Ireland</investigator_affiliation>
    <investigator_full_name>Prof Brian Lawlor</investigator_full_name>
    <investigator_title>Project Coordinator</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Investigator-driven clinical trial</keyword>
  <keyword>Nilvadipine</keyword>
  <keyword>Calcium Channel blocker</keyword>
  <keyword>Elderly</keyword>
  <keyword>Therapeutic Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nilvadipine</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

